Announcements Trials
Browse Landscape

Phase

Phase NA 20Phase EARLY_PHASE1 4Phase 1 4Phase 2 3Phase 1/2 1

Status

Active not recruiting 6Completed 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Osteosarcoma 1Neuroblastoma 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Blood Specimen Collection × Clear all
NCT03860207 2023-09-13

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Y-mAbs Therapeutics

Phase 1/2 Terminated
12 enrolled 15 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡